Virtual screening identifies broad-spectrum ?-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases.

ABSTRACT: Bacteria are known to evade ?-lactam antibiotic action by producing ?-lactamases (BLs), including carbapenemases, which are able to hydrolyze nearly all available ?-lactams. The production of BLs represents one of the best known and most targeted mechanisms of resistance in bacteria. We have performed the parallel screening of commercially available compounds against a panel of clinically relevant BLs: class A CTX-M-15 and KPC-2, subclass B1 NDM-1 and VIM-2 MBLs, and the class C P. aeruginosa AmpC. The results show that all BLs prefer scaffolds having electron pair donors: KPC-2 is preferentially inhibited by sulfonamide and tetrazole-based derivatives, NDM-1 by compounds bearing a thiol, a thiosemicarbazide or thiosemicarbazone moiety, while VIM-2 by triazole-containing molecules. Few broad-spectrum BLs inhibitors were identified; among these, compound 40 potentiates imipenem activity against an NDM-1-producing E. coli clinical strain. The binary complexes of the two most promising compounds binding NDM-1 and VIM-2 were obtained at high resolution, providing strong insights to improve molecular docking simulations, especially regarding the interaction of MBLs with inhibitors.

SUBMITTER: Spyrakis F 

PROVIDER: S-EPMC7391774 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature